CP
China Pharma Holdings, Inc.
CPHI · AMEX
$0.76 +2.05% (+$0.02)
1M -17.71%
Market Cap $30.5M
P/E Ratio -
Div. Yield -
ROE 17.14%
Bulios Fair Price
$0.38
49.7% downside
Current Price
$0.76
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CPHI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
53 /100
Fair P/B 0.84x
P/S 7.80x
EV/EBITDA N/A
Growth
22 /100
Declining Book val. growth 74.36%
Rev. growth 20.03%
FCF growth N/A
Profitability
0 /100
Weak Net margin 114.33%
Op. margin 111.84%
FCF margin 2,251,360.00%
Quality
1 /100
Poor ROE 17.14%
ROA 10.01%
Asset turnover 0.09x
Debt
46 /100
Moderate Current ratio 0.26x
Int. coverage -44.19x
Debt/Equity 0.10x
Stability
43 /100
Moderate Rev. volatility 14.32%
EPS volatility 132.92%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CPHI
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Zhilin Li
Employees
215
Headquarters
Haikou